Related Experiment Video
Updated: Feb 28, 2026
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
Remdesivir in COVID-19: A Focus on Pediatric Cardiac Patients
Dima Bsat1, Dalia Safi1, Mariam Arabi2
1Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon, aubmc.org.lb.
Insights
Remdesivir, an antiviral, was widely used for COVID-19 but its efficacy is debated, especially in children. More research is needed on its use in pediatric cardiac patients with COVID-19.
Area of Science:
- Pharmacology
- Virology
- Pediatrics
Background:
- The COVID-19 pandemic spurred the search for effective treatments.
- Remdesivir, an RNA-dependent RNA polymerase inhibitor, was a key antiviral investigated.
- Most studies on remdesivir efficacy focused on adult populations.
Purpose of the Study:
- To review the mechanism of action and efficacy of remdesivir against COVID-19.
- To specifically examine the under-investigated use of remdesivir in pediatric cardiac patients.
- To identify knowledge gaps regarding remdesivir's effectiveness in vulnerable pediatric populations.
Main Methods:
- Literature review of randomized controlled trials and retrospective studies.
- Analysis of studies involving both adult and pediatric populations.
- Focus on data concerning cardiac pediatric patients with COVID-19.
Main Results:
- Contradictory findings exist regarding remdesivir's efficacy in adults.
- Limited data available on remdesivir's effectiveness in pediatric populations.
- Pediatric cardiac patients represent a particularly vulnerable group with under-investigated treatment options.
Conclusions:
- Current literature shows significant gaps in understanding remdesivir's efficacy in pediatric cardiac patients.
- Further targeted studies are required to assess remdesivir's benefits and risks in specific pediatric age groups and comorbidities.
- Evidence-based treatment strategies for high-risk pediatric patients with COVID-19 need further development.
Abstract:
The coronavirus disease 2019 (COVID-19) pandemic has presented a significant global health challenge that necessitated the immediate search for various therapeutic modalities. Remdesivir, an antiviral drug inhibiting RNA-dependent RNA polymerase (RdRp), was among the most heavily used drugs against COVID-19. Of the several randomized controlled trials studying the efficacy of remdesivir, the vast majority were studied on the adult population. Results remain contradictory, with some studies supporting the high efficacy of remdesivir while others highlighting the lack of significance of its antiviral effects. Given the lack of focus on the pediatric population, the antiviral effects of remdesivir in cardiac pediatric patients, who are particularly vulnerable, remain especially under-investigated. This literature review explores current literature on remdesivir's mechanism of action and efficacy against COVID-19, especially in the pediatric cardiac population. Therefore, by combining results of studies from randomized controlled trials and retrospective studies in the adult and pediatric populations, this literature review underlines current knowledge gaps and highlights the need for studies targeting specific ages and comorbidities to effectively treat patients at higher risk of adverse events.
More Related Videos
07:41Insertion, Maintenance, and Removal of the Percutaneous Dual Lumen Cannula Right Ventricular Assist Device
Published on: July 20, 2022
08:41Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Related Concept Videos
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
01:14Myocarditis III: Medical Management
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
01:29Drug Dosing: Infants and Children